- Cardinal Health reported strong second-quarter results for fiscal year 2007, with revenue increasing 13% to $21.8 billion and earnings per share increasing 17% to $0.77.
- All four of Cardinal Health's continuing business segments experienced solid revenue and earnings growth. The company also plans to broaden its specialty pharmaceutical offerings through the acquisition of SpecialtyScripts Pharmacy.
- For the fiscal year, Cardinal Health reiterated its guidance range of $3.25 to $3.40 for non-GAAP diluted earnings per share from continuing operations.
- Cardinal Health reported third-quarter results with revenue increasing 8% to nearly $22 billion and a loss of $5 million or $0.01 per share due to a $600 million litigation reserve.
- On a non-GAAP basis, earnings from continuing operations increased 10% to $390 million or 16% to $0.96 per share.
- The company closed the $3.3 billion sale of its PTS business and repurchased $1.4 billion in shares during the quarter.
- Cardinal Health reported first quarter results for fiscal year 2007, with revenue increasing 11% to $21.4 billion and earnings from continuing operations rising 26% to $300 million.
- Key drivers of growth included strong performance in the Healthcare Supply Chain Services-Pharmaceutical segment due to higher generic drug sales and expense controls. The Medical Products Manufacturing segment also had solid results.
- For fiscal year 2007, Cardinal Health reiterated its outlook for non-GAAP diluted EPS from continuing operations to be in the range of $3.50 to $3.70.
Cardinal Health reported a 7% increase in second quarter revenue to $23 billion. Diluted earnings per share from continuing operations increased 16% to $0.89. However, Cardinal Health revised its full-year earnings per share guidance downward to a range of $3.75 to $3.85 due to issues affecting its pharmaceutical distribution business, including anti-diversion measures and contract repricings.
- Cardinal Health reported a 5% increase in third quarter revenue to $22.9 billion and GAAP EPS of $1.02, compared to a $0.01 loss in the prior year. Non-GAAP EPS increased 13% to $1.08.
- Revenue growth was driven by the healthcare supply chain medical segment and clinical and medical products sector. However, the supply chain pharmaceutical segment faced challenges including customer disruption and slower market growth.
- The company reaffirmed its fiscal year 2008 non-GAAP EPS guidance range of $3.75 to $3.85.
Cardinal Health reported second quarter results for fiscal year 2009, with revenue increasing 8% to $25 billion compared to the same period last year. GAAP earnings from continuing operations declined 2% to $319 million, while non-GAAP earnings increased 2% to $335 million. Both the Healthcare Supply Chain Services and Clinical and Medical Products segments saw revenue growth, with Healthcare Supply Chain Services segment profit increasing 6% and Clinical and Medical Products segment profit growing 16%. The company reaffirmed its full-year non-GAAP EPS guidance of $3.50 to $3.60.
Cardinal Health reported an 11% increase in revenue to $24 billion for the first quarter. Earnings per share declined 16% to $0.69 due to contract re-pricings and anti-diversion efforts. The healthcare supply chain services segment achieved double-digit revenue growth but profit declined 16% due to pricing issues. Clinical and medical products revenue grew 12% and profits grew 15% driven by continued strength in dispensing. Cardinal Health reiterated its full-year guidance range despite economic uncertainty.
Cardinal Health Q1 FY 2017 Earnings PresentationCardinal_Health
- Cardinal Health reported financial results for Q1 FY2017 with total revenue of $32.04 billion, up 14% year-over-year. However, operating earnings were $535 million, down 14% due to generic drug pricing pressures.
- The Pharmaceutical segment saw a 14% increase in revenue driven by growth from existing and new customers. However, segment profit decreased 19% to $534 million due to generic pricing declines and losing a large customer.
- The Medical segment reported a 12% revenue increase from acquisitions and new customers. Segment profit increased 26% to $127 million from contributions of acquisitions and Cardinal Health brand products.
J.P. Morgan 32nd Annual Healthcare Conference PresentationCardinal_Health
Cardinal Health presented at the 2014 J.P. Morgan Healthcare Conference. Cardinal Health has delivered strong financial growth and returns for shareholders through focused execution on strategic priorities. Over the past three years, Cardinal Health achieved 18.5% annual non-GAAP EPS growth and a 21.1% modified total shareholder return, expanded operating margins, and increased its dividend. Looking ahead, Cardinal Health aims to further grow through expanding offerings in high-potential areas like generics, specialty pharmaceuticals, alternate sites of care, and international markets to meet evolving healthcare needs.
- Cardinal Health reported third-quarter results with revenue increasing 8% to nearly $22 billion and a loss of $5 million or $0.01 per share due to a $600 million litigation reserve.
- On a non-GAAP basis, earnings from continuing operations increased 10% to $390 million or 16% to $0.96 per share.
- The company closed the $3.3 billion sale of its PTS business and repurchased $1.4 billion in shares during the quarter.
- Cardinal Health reported first quarter results for fiscal year 2007, with revenue increasing 11% to $21.4 billion and earnings from continuing operations rising 26% to $300 million.
- Key drivers of growth included strong performance in the Healthcare Supply Chain Services-Pharmaceutical segment due to higher generic drug sales and expense controls. The Medical Products Manufacturing segment also had solid results.
- For fiscal year 2007, Cardinal Health reiterated its outlook for non-GAAP diluted EPS from continuing operations to be in the range of $3.50 to $3.70.
Cardinal Health reported a 7% increase in second quarter revenue to $23 billion. Diluted earnings per share from continuing operations increased 16% to $0.89. However, Cardinal Health revised its full-year earnings per share guidance downward to a range of $3.75 to $3.85 due to issues affecting its pharmaceutical distribution business, including anti-diversion measures and contract repricings.
- Cardinal Health reported a 5% increase in third quarter revenue to $22.9 billion and GAAP EPS of $1.02, compared to a $0.01 loss in the prior year. Non-GAAP EPS increased 13% to $1.08.
- Revenue growth was driven by the healthcare supply chain medical segment and clinical and medical products sector. However, the supply chain pharmaceutical segment faced challenges including customer disruption and slower market growth.
- The company reaffirmed its fiscal year 2008 non-GAAP EPS guidance range of $3.75 to $3.85.
Cardinal Health reported second quarter results for fiscal year 2009, with revenue increasing 8% to $25 billion compared to the same period last year. GAAP earnings from continuing operations declined 2% to $319 million, while non-GAAP earnings increased 2% to $335 million. Both the Healthcare Supply Chain Services and Clinical and Medical Products segments saw revenue growth, with Healthcare Supply Chain Services segment profit increasing 6% and Clinical and Medical Products segment profit growing 16%. The company reaffirmed its full-year non-GAAP EPS guidance of $3.50 to $3.60.
Cardinal Health reported an 11% increase in revenue to $24 billion for the first quarter. Earnings per share declined 16% to $0.69 due to contract re-pricings and anti-diversion efforts. The healthcare supply chain services segment achieved double-digit revenue growth but profit declined 16% due to pricing issues. Clinical and medical products revenue grew 12% and profits grew 15% driven by continued strength in dispensing. Cardinal Health reiterated its full-year guidance range despite economic uncertainty.
Cardinal Health Q1 FY 2017 Earnings PresentationCardinal_Health
- Cardinal Health reported financial results for Q1 FY2017 with total revenue of $32.04 billion, up 14% year-over-year. However, operating earnings were $535 million, down 14% due to generic drug pricing pressures.
- The Pharmaceutical segment saw a 14% increase in revenue driven by growth from existing and new customers. However, segment profit decreased 19% to $534 million due to generic pricing declines and losing a large customer.
- The Medical segment reported a 12% revenue increase from acquisitions and new customers. Segment profit increased 26% to $127 million from contributions of acquisitions and Cardinal Health brand products.
J.P. Morgan 32nd Annual Healthcare Conference PresentationCardinal_Health
Cardinal Health presented at the 2014 J.P. Morgan Healthcare Conference. Cardinal Health has delivered strong financial growth and returns for shareholders through focused execution on strategic priorities. Over the past three years, Cardinal Health achieved 18.5% annual non-GAAP EPS growth and a 21.1% modified total shareholder return, expanded operating margins, and increased its dividend. Looking ahead, Cardinal Health aims to further grow through expanding offerings in high-potential areas like generics, specialty pharmaceuticals, alternate sites of care, and international markets to meet evolving healthcare needs.
Cardinal Health held an investor and analyst meeting to discuss its strategic priorities and growth opportunities. The company has demonstrated strong financial performance in recent years with increasing non-GAAP EPS, operating earnings, and operating margin rates on average of 18.5%, 13.6%, and 1.42-2.02% respectively from 2010-2013. Cardinal Health aims to sustain growth by focusing on key trends in healthcare including increased care in alternate sites, changes to reimbursement models, and the transition to value-based care. The company is well-positioned to support evolving health system needs through its expanding portfolio of cost-effective medical products and growing set of services across the care continuum.
This document summarizes a Cardinal Health investor presentation from June 17, 2016 in Dublin. The presentation included introductory comments from the Chairman and CEO George Barrett. It also featured overviews of initiatives in the Medical segment from CEO Don Casey and of the post-acute care management company naviHealth from CEO Clay Richards. The agenda allowed for question and answer sessions with leaders of both the Medical and Pharmaceutical segments as well as the CFO.
J.P. Morgan 33rd Annual Healthcare ConferenceCardinal_Health
This document contains the transcript from George S. Barrett's presentation at the J.P. Morgan Healthcare Conference on January 13, 2015. It discusses Cardinal Health's strategic priorities including growing its specialty pharmaceutical, generic drug sourcing, and international businesses. It also outlines opportunities in health system solutions, alternate sites of care, and the home healthcare market. The presentation notes Cardinal Health's sustained financial performance and future aspirations for metrics like operating margin and earnings growth. It emphasizes the company's focus on key trends in healthcare like increased consumerism, transition to value-based care, and continued innovation.
Cardinal Health held its 39th Annual Raymond James Institutional Investors Conference on March 6, 2018. Mike Kaufmann, Chief Executive Officer of Cardinal Health, discussed the company's financial results for FY17 and Q2FY18, highlighting revenue, operating earnings, and diluted EPS. Kaufmann also provided an overview of Cardinal Health's two reporting segments, the acquisition of Medtronic's Patient Recovery Business, and Cardinal Health's enterprise-wide capabilities in logistics solutions, business solutions, product solutions, and patient solutions.
Diplomat is a specialty pharmacy company that has experienced strong growth through expansion into new therapeutic areas and services. It focuses on specialty drugs like oncology that require complex care management. Diplomat has a unique limited distribution model that gives it exclusive access to certain specialty drugs, fueling its ability to gain market share. The company plans to continue its growth strategy through organic growth, acquisitions, and expanding relationships with drug manufacturers and payors.
- Cardinal Health reported financial results for its third quarter of fiscal year 2014, ended March 31, 2014.
- Total revenue decreased 13% to $18.8 billion compared to the same period last year, driven by the expiration of a contract with Walgreens, partially offset by growth with new and existing customers.
- Operating earnings were $508 million, a 7% increase, and non-GAAP operating earnings were $561 million, a 3% decrease.
- Cardinal Health reported financial results for its third quarter of fiscal year 2014, ended March 31, 2014.
- Total revenue decreased 13% to $18.8 billion compared to the same period last year, driven by the expiration of a contract with Walgreens, partially offset by growth with new and existing customers.
- Operating earnings were $508 million, a 7% increase, and non-GAAP operating earnings were $561 million, a 3% decrease.
Cardinal Health Q2 FY 2016 Earnings PresentationCardinal_Health
- Cardinal Health reported financial results for Q2 FY2016 with total revenue of $31.4 billion, a 23% increase over Q2 FY2015. Operating earnings were $563 million, a 3% increase.
- The Pharmaceutical segment saw a 25% revenue increase to $28.3 billion and a 16% increase in segment profit to $627 million due to growth from existing and new customers as well as acquisitions.
- The Medical segment reported a 9% revenue increase to $3.2 billion, while segment profit declined 8% to $106 million, which includes a $21 million impact from Cordis-related inventory fair value step-up.
Cardinal Health 2016 Annual Shareholder Meeting PresentationCardinal_Health
This document summarizes the annual shareholders meeting of Cardinal Health, Inc. held on November 3, 2016. It discusses Cardinal Health's transformation of healthcare delivery through various business lines and services. In fiscal year 2016, Cardinal Health achieved $121.5 billion in revenue, a 19% increase over the previous year. Non-GAAP diluted earnings per share were $5.24, a 20% increase. For fiscal year 2017, the company expects high single-digit revenue growth and non-GAAP diluted EPS between $5.40-$5.60.
- Cardinal Health reported financial results for its third quarter of fiscal year 2018, ending March 31, 2018.
- Total revenue increased 6% year-over-year to $33.6 billion. However, operating earnings decreased 10% to $546 million and net earnings decreased 33% to $255 million.
- The Pharmaceutical segment saw a 5% increase in revenue driven by sales growth, but segment profit decreased due to generic program performance. The Medical segment had a 15% revenue increase from acquisitions, and a 34% increase in segment profit.
- For fiscal year 2018, Cardinal Health expects revenue to increase by a mid-single digit percentage and non-GAAP EPS to be between $
Cardinal Health held its 39th Annual Raymond James Institutional Investors Conference on March 6, 2018. Mike Kaufmann, Chief Executive Officer of Cardinal Health, presented an overview of the company including:
- Cardinal Health is a global, integrated healthcare products and services company with two reporting segments - Pharmaceutical and Medical.
- In FY17, Cardinal Health acquired Medtronic's Patient Recovery Business for $6.1 billion to expand its medical product portfolio.
- Cardinal Health reported FY17 revenues of $129.9 billion and non-GAAP operating earnings of $2.769 billion. For Q2FY18, revenues were $35.186 billion and non-GAAP operating earnings were $730
- Cardinal Health reported Q4 FY2017 revenue of $32.966 billion, a 5% increase over the prior year. Operating earnings were $439 million, a 29% decrease.
- Revenue in the Pharmaceutical segment increased 5% to $29.552 billion driven by distribution customer and specialty solutions growth. Segment profit decreased 7% to $505 million due to generic pricing and IT investment.
- The Medical segment saw 6% revenue growth to $3.416 billion from new and existing customers. Segment profit rose 13% to $138 million from post-acute solutions and distribution growth.
This document summarizes Cardinal Health's investor and analyst meeting that took place on November 19, 2015. The agenda included an overview of healthcare strategy and financials, a discussion of the pharmaceutical and medical outlook, and a specialist physician panel. Cardinal Health's CEO discussed how the company is changing healthcare. Other presentations provided insights into healthcare trends, the consumer of 2020, value-based care, and Cardinal Health's financial performance and long-term growth aspirations.
Cardinal Health is a well-balanced, well-prepared, and well-focused healthcare services company. It has demonstrated a strong track record of consistent financial growth and returning substantial value to shareholders. Cardinal Health provides solutions across the full healthcare continuum and is well-positioned for future growth given key trends in healthcare. It focuses on strategic priorities like generics, specialty pharmaceuticals, international expansion, and solutions for health systems.
cardinal health Conference Call Presentationfinance2
Cardinal Health presented information on its planned spin-off of its clinical and medical products businesses into a separate company. It discussed the rationale for the separation, including allowing each business to focus on its strategic goals and access capital. It outlined key steps and milestones to completing the spin-off. Cardinal Health also presented overviews of the businesses that would comprise each company after the separation and their leadership teams, capital structures, and growth opportunities.
- Cardinal Health reported financial results for Q1 FY2018 with total revenue of $32.6 billion, a 2% increase over Q1 FY2017. However, operating earnings were $262 million, a 51% decrease from the previous year.
- Earnings per share for Q1 FY2018 were $0.36, down 63% from the prior year. The decreases in operating earnings and EPS were driven by lower generics program performance and costs associated with IT platform investments.
- The Pharmaceutical segment saw a 1% revenue increase but a 13% decrease in segment profit due to generics pricing changes partially offset by benefits from the Red Oak Sourcing venture. The Medical segment reported 14% revenue growth
Q1 fy15 earnings presentation final w schedulesCardinal_Health
- Cardinal Health reported financial results for Q1 FY2015 with total revenue of $24.07 billion, down 2% from the previous year. Operating earnings on a non-GAAP basis were $566 million, up 6% from the previous year.
- The Pharmaceutical segment saw a 3% decline in revenue to $21.2 billion due to the expiration of a contract in the prior year, but segment profit increased 4% to $451 million. The Medical segment grew revenue 5% and segment profit 6%.
- For FY2015, Cardinal Health expects non-GAAP EPS to be in the range of $4.10 to $4.30, up from $3.80 in F
Cardinal Health reported financial results for Q2 FY2014 with the following highlights:
- Revenue decreased 12% to $22.2 billion due to the expiration of the Walgreens contract.
- Operating earnings increased 2% to $519 million due to margin expansion in pharmaceutical programs and branded agreements.
- Earnings from continuing operations decreased 9% to $275 million.
- The company updated its FY2014 non-GAAP EPS guidance to $3.75-$3.85, representing year-over-year growth.
- Cardinal Health reported financial results for Q1 FY2016 with revenue increasing 17% year-over-year to $28.1 billion and non-GAAP diluted EPS increasing 38% to $1.38.
- The Pharmaceutical segment saw a 19% revenue increase to $25.1 billion and a 46% increase in segment profit to $657 million due to growth from existing and new customers.
- The Medical segment reported a 2% revenue increase to $2.9 billion but an 11% decline in segment profit to $101 million primarily due to Cardinal Health's Canada business.
- For FY2016, Cardinal Health expects mid-teens revenue growth and non-GAAP diluted EPS between
This document is McKesson Corporation's Form 10-Q quarterly report filed with the SEC for the quarter ended December 31, 2005. It provides financial statements and disclosures including the condensed consolidated balance sheet, income statement, cash flow statement, and notes to the financial statements. Key details include revenues of $22.6 billion for the quarter and $65.3 billion for the nine months, net income of $193 million for the quarter and $531 million for the nine months, and the acquisition of D&K Healthcare Resources for $479 million in cash during the quarter.
Cardinal Health held an investor and analyst meeting to discuss its strategic priorities and growth opportunities. The company has demonstrated strong financial performance in recent years with increasing non-GAAP EPS, operating earnings, and operating margin rates on average of 18.5%, 13.6%, and 1.42-2.02% respectively from 2010-2013. Cardinal Health aims to sustain growth by focusing on key trends in healthcare including increased care in alternate sites, changes to reimbursement models, and the transition to value-based care. The company is well-positioned to support evolving health system needs through its expanding portfolio of cost-effective medical products and growing set of services across the care continuum.
This document summarizes a Cardinal Health investor presentation from June 17, 2016 in Dublin. The presentation included introductory comments from the Chairman and CEO George Barrett. It also featured overviews of initiatives in the Medical segment from CEO Don Casey and of the post-acute care management company naviHealth from CEO Clay Richards. The agenda allowed for question and answer sessions with leaders of both the Medical and Pharmaceutical segments as well as the CFO.
J.P. Morgan 33rd Annual Healthcare ConferenceCardinal_Health
This document contains the transcript from George S. Barrett's presentation at the J.P. Morgan Healthcare Conference on January 13, 2015. It discusses Cardinal Health's strategic priorities including growing its specialty pharmaceutical, generic drug sourcing, and international businesses. It also outlines opportunities in health system solutions, alternate sites of care, and the home healthcare market. The presentation notes Cardinal Health's sustained financial performance and future aspirations for metrics like operating margin and earnings growth. It emphasizes the company's focus on key trends in healthcare like increased consumerism, transition to value-based care, and continued innovation.
Cardinal Health held its 39th Annual Raymond James Institutional Investors Conference on March 6, 2018. Mike Kaufmann, Chief Executive Officer of Cardinal Health, discussed the company's financial results for FY17 and Q2FY18, highlighting revenue, operating earnings, and diluted EPS. Kaufmann also provided an overview of Cardinal Health's two reporting segments, the acquisition of Medtronic's Patient Recovery Business, and Cardinal Health's enterprise-wide capabilities in logistics solutions, business solutions, product solutions, and patient solutions.
Diplomat is a specialty pharmacy company that has experienced strong growth through expansion into new therapeutic areas and services. It focuses on specialty drugs like oncology that require complex care management. Diplomat has a unique limited distribution model that gives it exclusive access to certain specialty drugs, fueling its ability to gain market share. The company plans to continue its growth strategy through organic growth, acquisitions, and expanding relationships with drug manufacturers and payors.
- Cardinal Health reported financial results for its third quarter of fiscal year 2014, ended March 31, 2014.
- Total revenue decreased 13% to $18.8 billion compared to the same period last year, driven by the expiration of a contract with Walgreens, partially offset by growth with new and existing customers.
- Operating earnings were $508 million, a 7% increase, and non-GAAP operating earnings were $561 million, a 3% decrease.
- Cardinal Health reported financial results for its third quarter of fiscal year 2014, ended March 31, 2014.
- Total revenue decreased 13% to $18.8 billion compared to the same period last year, driven by the expiration of a contract with Walgreens, partially offset by growth with new and existing customers.
- Operating earnings were $508 million, a 7% increase, and non-GAAP operating earnings were $561 million, a 3% decrease.
Cardinal Health Q2 FY 2016 Earnings PresentationCardinal_Health
- Cardinal Health reported financial results for Q2 FY2016 with total revenue of $31.4 billion, a 23% increase over Q2 FY2015. Operating earnings were $563 million, a 3% increase.
- The Pharmaceutical segment saw a 25% revenue increase to $28.3 billion and a 16% increase in segment profit to $627 million due to growth from existing and new customers as well as acquisitions.
- The Medical segment reported a 9% revenue increase to $3.2 billion, while segment profit declined 8% to $106 million, which includes a $21 million impact from Cordis-related inventory fair value step-up.
Cardinal Health 2016 Annual Shareholder Meeting PresentationCardinal_Health
This document summarizes the annual shareholders meeting of Cardinal Health, Inc. held on November 3, 2016. It discusses Cardinal Health's transformation of healthcare delivery through various business lines and services. In fiscal year 2016, Cardinal Health achieved $121.5 billion in revenue, a 19% increase over the previous year. Non-GAAP diluted earnings per share were $5.24, a 20% increase. For fiscal year 2017, the company expects high single-digit revenue growth and non-GAAP diluted EPS between $5.40-$5.60.
- Cardinal Health reported financial results for its third quarter of fiscal year 2018, ending March 31, 2018.
- Total revenue increased 6% year-over-year to $33.6 billion. However, operating earnings decreased 10% to $546 million and net earnings decreased 33% to $255 million.
- The Pharmaceutical segment saw a 5% increase in revenue driven by sales growth, but segment profit decreased due to generic program performance. The Medical segment had a 15% revenue increase from acquisitions, and a 34% increase in segment profit.
- For fiscal year 2018, Cardinal Health expects revenue to increase by a mid-single digit percentage and non-GAAP EPS to be between $
Cardinal Health held its 39th Annual Raymond James Institutional Investors Conference on March 6, 2018. Mike Kaufmann, Chief Executive Officer of Cardinal Health, presented an overview of the company including:
- Cardinal Health is a global, integrated healthcare products and services company with two reporting segments - Pharmaceutical and Medical.
- In FY17, Cardinal Health acquired Medtronic's Patient Recovery Business for $6.1 billion to expand its medical product portfolio.
- Cardinal Health reported FY17 revenues of $129.9 billion and non-GAAP operating earnings of $2.769 billion. For Q2FY18, revenues were $35.186 billion and non-GAAP operating earnings were $730
- Cardinal Health reported Q4 FY2017 revenue of $32.966 billion, a 5% increase over the prior year. Operating earnings were $439 million, a 29% decrease.
- Revenue in the Pharmaceutical segment increased 5% to $29.552 billion driven by distribution customer and specialty solutions growth. Segment profit decreased 7% to $505 million due to generic pricing and IT investment.
- The Medical segment saw 6% revenue growth to $3.416 billion from new and existing customers. Segment profit rose 13% to $138 million from post-acute solutions and distribution growth.
This document summarizes Cardinal Health's investor and analyst meeting that took place on November 19, 2015. The agenda included an overview of healthcare strategy and financials, a discussion of the pharmaceutical and medical outlook, and a specialist physician panel. Cardinal Health's CEO discussed how the company is changing healthcare. Other presentations provided insights into healthcare trends, the consumer of 2020, value-based care, and Cardinal Health's financial performance and long-term growth aspirations.
Cardinal Health is a well-balanced, well-prepared, and well-focused healthcare services company. It has demonstrated a strong track record of consistent financial growth and returning substantial value to shareholders. Cardinal Health provides solutions across the full healthcare continuum and is well-positioned for future growth given key trends in healthcare. It focuses on strategic priorities like generics, specialty pharmaceuticals, international expansion, and solutions for health systems.
cardinal health Conference Call Presentationfinance2
Cardinal Health presented information on its planned spin-off of its clinical and medical products businesses into a separate company. It discussed the rationale for the separation, including allowing each business to focus on its strategic goals and access capital. It outlined key steps and milestones to completing the spin-off. Cardinal Health also presented overviews of the businesses that would comprise each company after the separation and their leadership teams, capital structures, and growth opportunities.
- Cardinal Health reported financial results for Q1 FY2018 with total revenue of $32.6 billion, a 2% increase over Q1 FY2017. However, operating earnings were $262 million, a 51% decrease from the previous year.
- Earnings per share for Q1 FY2018 were $0.36, down 63% from the prior year. The decreases in operating earnings and EPS were driven by lower generics program performance and costs associated with IT platform investments.
- The Pharmaceutical segment saw a 1% revenue increase but a 13% decrease in segment profit due to generics pricing changes partially offset by benefits from the Red Oak Sourcing venture. The Medical segment reported 14% revenue growth
Q1 fy15 earnings presentation final w schedulesCardinal_Health
- Cardinal Health reported financial results for Q1 FY2015 with total revenue of $24.07 billion, down 2% from the previous year. Operating earnings on a non-GAAP basis were $566 million, up 6% from the previous year.
- The Pharmaceutical segment saw a 3% decline in revenue to $21.2 billion due to the expiration of a contract in the prior year, but segment profit increased 4% to $451 million. The Medical segment grew revenue 5% and segment profit 6%.
- For FY2015, Cardinal Health expects non-GAAP EPS to be in the range of $4.10 to $4.30, up from $3.80 in F
Cardinal Health reported financial results for Q2 FY2014 with the following highlights:
- Revenue decreased 12% to $22.2 billion due to the expiration of the Walgreens contract.
- Operating earnings increased 2% to $519 million due to margin expansion in pharmaceutical programs and branded agreements.
- Earnings from continuing operations decreased 9% to $275 million.
- The company updated its FY2014 non-GAAP EPS guidance to $3.75-$3.85, representing year-over-year growth.
- Cardinal Health reported financial results for Q1 FY2016 with revenue increasing 17% year-over-year to $28.1 billion and non-GAAP diluted EPS increasing 38% to $1.38.
- The Pharmaceutical segment saw a 19% revenue increase to $25.1 billion and a 46% increase in segment profit to $657 million due to growth from existing and new customers.
- The Medical segment reported a 2% revenue increase to $2.9 billion but an 11% decline in segment profit to $101 million primarily due to Cardinal Health's Canada business.
- For FY2016, Cardinal Health expects mid-teens revenue growth and non-GAAP diluted EPS between
This document is McKesson Corporation's Form 10-Q quarterly report filed with the SEC for the quarter ended December 31, 2005. It provides financial statements and disclosures including the condensed consolidated balance sheet, income statement, cash flow statement, and notes to the financial statements. Key details include revenues of $22.6 billion for the quarter and $65.3 billion for the nine months, net income of $193 million for the quarter and $531 million for the nine months, and the acquisition of D&K Healthcare Resources for $479 million in cash during the quarter.
El documento presenta información sobre diferentes opciones de educación, incluyendo un Instituto de Capacitación y Educación Profesional, un Instituto de Desarrollo de Competencias Educativas, un programa llamado ConectoLugar para educación presencial o a distancia de manera escolarizada u abierta, así como una Convocatoria Prepa en Línea de la SEP para educación no presencial.
Specializing in restaurant food photography & video for social media & website in the North Haven, Connecticut area. Unique sports photography, event candids & super cool content creation.
The document discusses mobile reference applications from SAP that demonstrate end-to-end integration of technologies like SAP NetWeaver Gateway, SAP Mobile Platform, and SAPUI5. It aims to help developers and partners integrate these technologies more easily. The presentation covers challenges developers face, an overview and objectives of reference applications, detailed architecture, a demo, and an example of end-to-end integration using a mobile retailing application built with SAPUI5.
El documento describe cómo crear y modificar índices en Microsoft Word. Explica cómo marcar entradas de índice para palabras, frases o temas que se extienden a lo largo de varias páginas, seleccionar un diseño de índice e insertarlo en el documento. También cubre cómo actualizar un índice existente, modificar o eliminar entradas de índice y actualizar el índice resultante.
Keresőoptimalizálás mobilon: az mSEO eszközeiNorbert Boros
A mobil internet és az okostelefon penetráció növekedésével a mobil keresések aránya is emelkedőben van. Fel kell készülni a mobil SEO eszközeivel, amelyek hasonlatosak a desktop keresőoptimalizáláshoz, de van néhány további faktor is.
BenchMarker Issue 4 2012 -- India EditionSewells MSXI
The article discusses 5 common mistakes that car dealers make when posting on Facebook. They are: 1) Posts that are too wordy, exceeding 250 characters; 2) Lack of consistency in posting; 3) Irrelevant content that does not engage the local community; 4) Lack of valuable content such as maintenance tips; 5) No calls for interaction or ways for users to engage with the content. The article provides tips on how to improve Facebook presence, such as keeping posts short, posting regularly at peak times, including local community content, and providing value to users.
Este documento analiza críticamente los problemas del desarrollo y contexto latinoamericano a través del caso de Bogotá. Discute los retos de la urbanización en la Sabana de Bogotá, incluyendo la expansión no planificada de la ciudad y los impactos ambientales. También examina la propuesta para urbanizar la Reserva Van der Hammen y la oposición a esta medida, argumentando que el desarrollo debe basarse en la sostenibilidad ambiental.
Talk for the Project Quality Day at Eclipse Conference Europe 2015. A presentation on how to perform risk based testing, using Jira, Jubula and Mylyn (and Spago4Q), appplied to a real-world use case, the SpagoWorld Shop
Este documento define la auditoría como un conjunto de actividades dirigidas a obtener datos sobre los índices de calidad de los productos de manera oportuna y precisa. Explica que la auditoría permite una revisión independiente para evaluar las actividades y operaciones de una organización y asegurar que se realicen correctamente. También destaca la importancia de que el auditor mantenga independencia para evitar influencias en los resultados. Por último, define la seguridad de la información como la protección de los sistemas e información contra accesos, usos o daños no autor
E government dan penerepannya di kota bandung jawa baratJulio Mamesah
Dokumen tersebut membahas tentang e-government dan penilaian terhadap kualitas situs web pemerintah kota Bandung berdasarkan beberapa parameter. Beberapa poin penting yang diangkat antara lain peningkatan kualitas layanan pemerintah kepada masyarakat melalui teknologi informasi, penilaian bobot nilai e-government kota Bandung pada sektor Government to Business yang mendapat skor cukup tinggi, serta sarana komunikasi interaktif antara pemerintah dan pelaku
Apache Hadoop and Spark are best-of-breed technologies for distributed processing and storage of very large data sets: Big Data. Join us as we explain how to integrate Salesforce with off-the-shelf big data tools to build flexible applications. You'll also learn how Force.com is evolving in this area and how Big Objects and Data Pipelines will provide Big Data capability within the platform.
(359)long pdf repasando la comision angelidesManfredNolte
el pleno del Congreso español ha aprobado por unanimidad la constitución de una comisión que investigue las causas y consecuencias d la crisis financiera
This document provides an unboxing and first impressions of the Canon EOS 550D DSLR camera. The author notes the camera has a good grip but could be more ergonomic, smooth buttons, a huge display, high ISO image quality, extraordinary video abilities, and wonderful HDMI and external mic connectivity. They conclude it is the best deal and encourage getting one.
cardinal health Q1 2009 Earnings Transcriptfinance2
- Cardinal Health reported financial results for Q1 2009 with overall double-digit revenue and profit growth. Revenue increased 11% to $24.3 billion while operating earnings decreased 6% to $482 million.
- Earnings from continuing operations decreased 16% to $268 million due to weaker performance from HSCS, increased interest and other expenses, and a higher tax rate.
- HSCS revenue increased 11% to $23.4 billion due to strong growth across medical and pharmaceutical businesses. However, segment profit decreased 16% due to previously announced customer repricing.
- CMP revenue increased 12% to due to product installations, international growth, and acquisitions. Segment profit increased 15% due to
Morgan Stanley reported a 35% increase in earnings per share for the first quarter of 2004 compared to the first quarter of 2003. Net income for the quarter was $1.2 billion, up 35% from the prior year. Revenues were $6.2 billion for the quarter, a 14% increase from the first quarter of 2003, driven by strong performance in sales and trading businesses. The company saw record revenues and market share gains in investment banking during the quarter.
Proxy Statement for July 2004 Annual Meeting finance2
The 2004 Annual Meeting of Stockholders of McKesson Corporation will be held on July 28, 2004. The meeting will address electing three directors to three-year terms, ratifying the appointment of Deloitte & Touche LLP as independent auditors for fiscal year 2005, and any other business properly brought before the meeting. Stockholders of record as of June 1, 2004 are entitled to vote.
Morgan Stanley reported third quarter results, with earnings per share of $1.38, down from $1.50 in the previous year. Net revenues increased 13% to $8 billion, though expenses also rose 18%. For the first nine months of the year, the company achieved record net revenues and earnings per share. While most business lines performed well, losses from credit products and quantitative trading strategies reduced profits.
This document is a press release from Cardinal Health announcing their fiscal 2008 results and fiscal 2009 outlook. Some key points:
- Fiscal 2008 revenue increased 5% to $91 billion and GAAP EPS increased 76% to $3.64. Non-GAAP EPS grew 11% to $3.80.
- The company is exploring a potential spin-off of their clinical and medical products businesses into a separate publicly traded company.
- For fiscal 2009, revenue is expected to grow 6-7% while non-GAAP EPS is expected to be between $3.80-$3.95, though investments in R&D and IT may impact near-term growth.
- Challenges in the
35th Annual J.P. Morgan Healthcare Conference PresentationCardinal_Health
George S. Barrett, Chairman and CEO of Cardinal Health, gave a presentation at the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017. In the presentation, Barrett discussed how Cardinal Health is changing healthcare by bringing scaled solutions to help customers navigate a complex industry. He outlined key trends shaping the next five years in healthcare and how Cardinal Health is positioned for growth and success through strategic priorities that align with these trends. Barrett also reviewed Cardinal Health's financial performance and goals over the past five years.
Cardinal Health Q4 FY 2016 Earnings PresentationCardinal_Health
- Cardinal Health reported Q4 FY2016 revenue of $31.4 billion, a 14% increase over Q4 FY2015. Operating earnings increased 11% to $620 million.
- For FY2016, Cardinal Health reported record revenue of $121.5 billion, a 19% increase over FY2015. Operating earnings increased 14% to $2.5 billion.
- For FY2017, Cardinal Health expects revenue to increase in the high-single digit percentage range compared to FY2016. Non-GAAP diluted EPS is expected to be between $5.48 to $5.73.
Cardinal Health Q3 FY 2016 Earnings PresentationCardinal_Health
- Cardinal Health reported revenue of $30.7 billion for Q3 FY2016, a 21% increase over the previous year. Operating earnings increased 11% to $656 million.
- Revenue growth was driven by contributions from acquisitions as well as growth with new and existing customers in both the Pharmaceutical and Medical segments.
- The company updated full-year FY2016 guidance, expecting revenue growth in the mid- to high-teens percentage range over FY2015 and non-GAAP diluted EPS between $5.17 to $5.27.
Quest Diagnostics held a second quarter 2005 conference call to discuss financial results.
- Revenues grew 6.2% to $1.6 billion driven by a 5.3% increase in testing volume and a 1.2% increase in revenue per test.
- Earnings per share grew 14% to $0.59, and operating income margin expanded.
- Guidance for 2005 was reiterated with earnings per share growth of 14-16% and revenue growth of 5-6% expected.
- Cardinal Health is a global integrated healthcare services and products company with FY17 revenues of $129.9 billion. It operates through two segments: Pharmaceutical and Medical.
- In July 2017, Cardinal Health acquired Medtronic's Patient Recovery Business for $6.1 billion to expand its medical product portfolio. The acquisition is expected to contribute over $0.21 per share in FY18 and over $0.55 per share in FY19.
- Cardinal Health provides solutions to customers across its four focus areas of logistics, business solutions, product solutions, and patient solutions to enable more efficient healthcare delivery and connections between clinicians and patients.
Cardinal Health reported financial results for Q3 FY2017 with total revenue of $31.8 billion, up 4% from the previous year. Operating earnings were $605 million, down 8% due to generic drug pricing pressures and investments in IT systems. The outlook for FY2017 expects revenue to increase in the mid-to-high single digit percentage range with non-GAAP diluted EPS expected between $5.24-$5.50. Key assumptions include continued generic drug price deflation, brand drug price inflation, and contributions from acquisitions offset by lower benefits from generic launches and Red Oak Sourcing.
BD is a medical technology company that manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. In 2005, BD achieved revenue growth of 9.7% and income growth of 18.8%, while returning 60% of operating cash flow to shareholders through stock repurchases and dividends. The CEO highlighted progress in operational effectiveness, new product launches, revenue growth in all business segments, and contributions to global healthcare through philanthropic efforts and disaster relief.
1) Quest Diagnostics had an excellent first quarter with revenues growing 18%, earnings per share growing 13%, and strong cash generation of $241 million.
2) The company is seeing benefits from investments in new and innovative tests that are enhancing its value proposition.
3) After consideration, Quest decided to discontinue operations at its struggling test kit manufacturing subsidiary NID, which will reduce ongoing losses but result in restructuring charges in the second quarter.
- Cardinal Health reported financial results for Q2 FY2017 with total revenue of $33.15 billion, a 5% increase over the prior year. Operating earnings were $542 million, a 4% decrease.
- The Pharmaceutical segment saw 5% revenue growth but a 14% decline in segment profit due to generic drug pricing and loss of a customer. The Medical segment had 8% revenue growth and 50% increase in segment profit driven by contributions from Cordis.
- For FY2017, Cardinal expects revenue growth in the high-single digits and non-GAAP diluted EPS between $5.35-$5.50, up from $5.24 in FY2016. The Pharmaceutical segment outlook
Tenet Healthcare's CEO presented at the J.P. Morgan Healthcare Conference on January 11, 2022. Over the past several years, Tenet has transformed its portfolio, restructured operations, and improved quality and safety outcomes. It has demonstrated resiliency during the COVID-19 pandemic by consistently meeting or beating quarterly earnings guidance. Tenet aims to continue this growth trajectory by enhancing specialty care access, scaling its ambulatory surgery platform, and leading new high acuity services in lower cost settings.
J.P. Morgan 34th Annual Healthcare Conference PresentationCardinal_Health
This document is a presentation from Cardinal Health's Chairman and CEO George Barrett given at the J.P. Morgan Healthcare Conference on January 12, 2016. The presentation provides an overview of Cardinal Health, including key facts about the company, its two business segments and growth drivers, financial highlights and goals, capital deployment, and positioning in the changing healthcare industry. It emphasizes Cardinal Health's focus on serving customers across the care continuum.
Air Products reported record quarterly and annual financial results. For Q4, net income was $293 million, up 128% from the prior year. For fiscal 2007, sales reached $10 billion for the first time, up 15% from the prior year, net income was $1 billion, up 43%, and EPS was $4.64, up 46%. The company expects continued double-digit earnings growth in fiscal 2008 and targets expanding margins and reducing costs further.
This document summarizes a conference call by Quest Diagnostics about their third quarter 2005 financial results. Key points include:
- Revenues grew 6.4%, earnings per share were $0.66, and cash flow was $178 million.
- Clinical testing revenues grew 7.1% due to increased volume and revenue per test. Hurricanes Katrina and Rita reduced revenues by 0.5%.
- Operating income was 17.7% of revenues compared to 18% last year. Margins increased in clinical testing but were reduced by hurricanes and a $6.2 million charge.
- Their test kit manufacturing subsidiary NID performed below last year, reducing revenue growth by 0.5% and margin expansion
P&G Delivers Double-Digit Sales Growth in First Quarterfinance3
P&G reported double-digit sales growth in the first quarter, exceeding Wall Street earnings estimates. Unit volume grew 13% driven by double-digit growth in fabric and home care and health care. Net sales increased 11% to $10.8 billion. Core earnings per share grew 17% to $1.12 per share, beating consensus estimates by two cents. The company expects high single-digit volume growth and mid to upper single-digit sales growth in the second quarter. For the fiscal year, sales growth of 4-6% and double-digit earnings per share growth are expected.
United Health Group [PDF Document] Earnings Releasefinance3
UnitedHealth Group reported financial results for the fourth quarter and full year 2006. Fourth quarter revenues exceeded $18.1 billion, a 47% increase over the previous year. Full year revenues reached $71.68 billion, a 54% increase. Net earnings for the fourth quarter were $1.2 billion and $4.174 billion for the full year. The company affirmed projected 2007 net income in the range of $4.7-4.75 billion, including $980 million to $1 billion in Q1 2007.
- Cardinal Health reported financial results for Q2 FY2018 with total revenue of $35.2 billion, a 6% increase over Q2 of FY2017. Operating earnings on a GAAP basis were $399 million, a 26% decrease compared to the same period last year. However, non-GAAP operating earnings were $730 million, a 4% increase from Q2 of FY2017.
- The Pharmaceutical segment saw a 5% increase in revenue driven by growth in pharmaceutical and specialty distribution customers, but a 4% decrease in segment profits due to IT investment costs and generics program performance. The Medical segment reported a 19% revenue increase and 38% segment profit growth due to contributions from the recently
George S. Barrett, Chairman and Chief Executive Officer of Cardinal Health, presided over the company's Annual Meeting of Shareholders on November 8, 2017. The agenda included matters to be voted on such as electing directors, ratifying the independent auditor, and advisory votes on executive compensation. Barrett discussed Cardinal Health's acquisition of the Patient Recovery business and highlighted the company's strong financial performance over the past five years. He also outlined Cardinal Health's strategies focused on long-term shareholder value creation and balanced capital deployment.
This document provides an overview of Invitae Corporation's Q1 2018 conference call. Some key points:
- Invitae saw exceptional growth across key indicators like volume, revenue, and gross profit in Q1 2018.
- Operating expenses increased at a slower rate than volume growth, demonstrating operating leverage.
- The company strengthened its balance sheet, ending Q1 2018 with $60.6M in cash and investments.
- Invitae expects to continue driving down costs and increasing volume, revenue, and gross margin over 2018 to reach its goal of serving over 275,000 samples for the year.
Avery Dennison reported their second quarter earnings for 2006. Earnings per share from continuing operations increased 8% to $0.96 compared to the previous year. Excluding restructuring charges, earnings per share increased 9% to $0.99. Net sales were approximately even with the previous year at $1.41 billion, with organic sales growth of 2%. The company raised their estimated annual savings from restructuring efforts to between $85-100 million. Segment highlights included a 1% sales increase for Pressure-sensitive Materials and a 6% sales increase for Retail Information Services.
Similar to cardinal health Q2 2007 Earnings Release (20)
The Home Depot Celebrates Hispanic Culture Through Color and Paint With Color...finance2
The Home Depot launched a new Hispanic-inspired paint color palette called Colores Origenes, featuring over 70 vibrant colors with Spanish names to reflect Latin American culture. Research showed painting is very popular among Hispanics, 59% of whom speak Spanish at home. The new paint line and increased Spanish signage and materials aim to better serve the growing Hispanic community. It was created with Behr Paint and will be sold exclusively at select Home Depot stores.
The Home Depot and AARP Launch Nationwide Workshopsfinance2
The Home Depot and AARP launched nationwide home improvement workshops customized for those aged 50 and over. The workshops will cover topics like home modifications for comfort and safety, saving money on energy bills, and basic maintenance. The workshops are part of an alliance between the two organizations to provide resources for aging homeowners as around 86 million Americans are currently over 50, comprising over 40% of the population.
Nearly Half of Americans Fail to Check Home Safety Devices at Daylight-Saving...finance2
A survey found that 47% of Americans did not check their home safety devices when changing their clocks for daylight saving time last year. Nearly three-quarters did not know when daylight saving time ends this year on October 30th. The Home Depot recommends using the end of daylight saving time as a reminder to check smoke detectors and carbon monoxide detectors by changing their batteries.
View Summary The Home Depot Celebrates the Olympic Spirit With Special Kids...finance2
The Home Depot announced a special Olympic-themed Kids Workshop to be held on November 5, 2005 at its stores nationwide. Children will build a wooden bobsled toy to celebrate the 2006 Winter Olympics. Selected stores will host Olympic athletes to help children and promote the Olympics. The Home Depot aims to teach kids DIY skills through these monthly workshops and has hosted over 13 million children since 1997.
The Home Depot Announces First Quarter Resultsfinance2
The Home Depot reported first quarter earnings of $356 million, down from $1 billion in the same period last year. This included a $543 million non-recurring charge for closing underperforming stores. Excluding this charge, earnings were $697 million. Sales decreased 3.4% to $17.9 billion due to a 6.5% drop in comparable store sales. The company's CEO acknowledged difficult market conditions and said the company would focus on investing in existing stores.
1) The document discusses Home Depot's merchandising strategy, which focuses on national brands, exclusive proprietary brands, and serving core customers through product knowledge transfer.
2) Home Depot aims to aggressively attack the market through its brand strategies, which leverage national brands, exclusive brands, and proprietary brands to differentiate, build preference, and offer selection.
3) Home Depot is transforming its merchandising approach through investments in talent, focused processes like seasonal planning and presentation, and new systems that provide merchants better data and tools.
home depot 2008 Annual Meeting of Stockholdersfinance2
This document summarizes The Home Depot's 2008 Annual Meeting of Shareholders. It provides an overview of the company's financial performance in 2007, including a 2% decrease in sales and an 11% decrease in net earnings per share. It also outlines the company's five priorities for 2007 which were investing in associate engagement, shopping environment, product availability, product excitement, and owning the professional customer. The outlook anticipates 2008 will be another difficult year with guidance for a 4-5% sales decrease and a 19-24% decrease in earnings per share. The company will continue investing in its key priorities and allocating capital efficiently.
The document is a transcript from The Home Depot's 2008 Investor Day conference. Frank Blake, the company's CEO, provides an overview of the company's strategic focus on improving the core retail business, exercising disciplined capital allocation, increasing returns on existing assets, and building sustained competitive advantages. He highlights progress made on priorities like associate engagement and product availability. While housing market conditions remain difficult, Blake emphasizes the company's long term strategy and goals, such as becoming a best in class merchandiser.
This document provides a financial overview and discussion of Home Depot's performance in Q1 2008 and outlook for 2008. Some key points:
- Q1 2008 sales were down 3.4% and operating income was down 56.5% due to housing market challenges.
- For 2008, Home Depot expects total sales to decline 4-5%, negative comps in the mid-to-high single digits, and operating margin decline of 170-210 basis points.
- Home Depot has a staggered debt maturity schedule with low refinancing risk and strong cash flow and liquidity.
- The company is focused on capital efficiency through store rationalization, supply chain improvements, and driving productivity across operations
Paul Raines discusses Home Depot's focus on store operations and customers. Key points include:
1) Home Depot has made multi-year investments to improve labor standards, launch an "Aprons on the Floor" program, and focus on foundational improvements like maintenance and store standards.
2) The company is focusing on two customer segments - professional contractors and multicultural customers - through programs like product knowledge certification for associates, understanding each group's purchasing patterns, and targeted marketing.
3) Initiatives like daytime freight, call center closures, and a new merchandising team have helped exceed Home Depot's $180 million goal in operating cost reductions to reinvest in labor.
home depot http://ir.homedepot.com/common/download/download.cfm?companyid=HD&...finance2
This document discusses Home Depot's supply chain transformation efforts from 2007 to 2008. It outlines goals of improving product availability, inventory management, and developing an optimal distribution network. Home Depot implemented regional distribution centers (RDCs) to better aggregate store orders, improve in-stock levels, and reduce supply chain costs. The RDCs were shown to simplify operations and had benefits including increased gross margins and improved inventory turns that could generate $1.5 billion in additional cash.
The document discusses a decline in private residential investment and subprime/Alt-A mortgages over the past few years which has negatively impacted the housing market. It then outlines Home Depot's strategic focus on increasing returns through disciplined capital allocation, investing in existing assets like employee training and supply chain improvements, and building sustained competitive advantages. Home Depot expects another difficult year in 2008 but believes these strategic initiatives position it for stronger future growth once market conditions normalize.
home depotForward Looking & Non-GAAP Disclosures finance2
The document discusses forward-looking statements made in today's presentations regarding the home improvement and housing markets, earnings guidance, and other factors affecting earnings and sales. It notes these statements are based on currently available information and expectations that could change. It also discusses non-GAAP financial measurements included in today's presentations, including total adjusted debt and earnings measures that exclude expected costs associated with store closures and pipeline changes. These supplemental measures are not a substitute for GAAP but provide useful information to investors.
home depot Bank of America 38th Annual Investment Conferencefinance2
Carol Tomé and Mark Holifield presented at the Bank of America 38th Annual Investment Conference. The presentation discussed (1) Home Depot's progress on five priorities including implementing store standards and supply chain improvements, (2) the evolution of Home Depot's capital efficiency strategy through investing in priorities and rationalizing non-core assets, and (3) expected benefits from supply chain improvements including gross margin expansion and $1.5 billion additional cash from reducing inventory turns.
- The Home Depot reported third quarter earnings for fiscal year 2008, with sales of $17.8 billion, down 6.2% from the previous year, and same-store sales down 8.3%. Earnings per share were $0.45.
- Challenging housing and home improvement markets continued to pressure results. Previously strong regions like the Northwest saw double-digit negative comps.
- While sales were weak across most departments, building materials had positive comps led by roofing and insulation. Initiatives to improve merchandising and focus on value are showing early signs of success through improved transactions, market share gains, and gross margin expansion despite volatile costs.
- Tightening credit availability also
- The Home Depot reported third quarter earnings for fiscal year 2008, with sales of $17.8 billion, down 6.2% from the previous year, and same-store sales down 8.3%. Earnings per share were $0.45.
- Challenging housing and home improvement markets continued to pressure results. Previously strong regions like the Northwest saw double-digit negative comps.
- While sales were weak across most departments, building materials had positive comps led by roofing and insulation. Initiatives to improve merchandising and focus on value are showing early signs of success through improved transactions, market share gains, and gross margin expansion despite volatile costs.
- Tightening credit availability also
Budgeting as a Control Tool in Government Accounting in Nigeria
Being a Paper Presented at the Nigerian Maritime Administration and Safety Agency (NIMASA) Budget Office Staff at Sojourner Hotel, GRA, Ikeja Lagos on Saturday 8th June, 2024.
University of North Carolina at Charlotte degree offer diploma Transcripttscdzuip
办理美国UNCC毕业证书制作北卡大学夏洛特分校假文凭定制Q微168899991做UNCC留信网教留服认证海牙认证改UNCC成绩单GPA做UNCC假学位证假文凭高仿毕业证GRE代考如何申请北卡罗莱纳大学夏洛特分校University of North Carolina at Charlotte degree offer diploma Transcript
Economic Risk Factor Update: June 2024 [SlideShare]Commonwealth
May’s reports showed signs of continued economic growth, said Sam Millette, director, fixed income, in his latest Economic Risk Factor Update.
For more market updates, subscribe to The Independent Market Observer at https://blog.commonwealth.com/independent-market-observer.
In World Expo 2010 Shanghai – the most visited Expo in the World History
https://www.britannica.com/event/Expo-Shanghai-2010
China’s official organizer of the Expo, CCPIT (China Council for the Promotion of International Trade https://en.ccpit.org/) has chosen Dr. Alyce Su as the Cover Person with Cover Story, in the Expo’s official magazine distributed throughout the Expo, showcasing China’s New Generation of Leaders to the World.
Discovering Delhi - India's Cultural Capital.pptxcosmo-soil
Delhi, the heartbeat of India, offers a rich blend of history, culture, and modernity. From iconic landmarks like the Red Fort to bustling commercial hubs and vibrant culinary scenes, Delhi's real estate landscape is dynamic and diverse. Discover the essence of India's capital, where tradition meets innovation.
The Rise and Fall of Ponzi Schemes in America.pptxDiana Rose
Ponzi schemes, a notorious form of financial fraud, have plagued America’s investment landscape for decades. Named after Charles Ponzi, who orchestrated one of the most infamous schemes in the early 20th century, these fraudulent operations promise high returns with little or no risk, only to collapse and leave investors with significant losses. This article explores the nature of Ponzi schemes, notable cases in American history, their impact on victims, and measures to prevent falling prey to such scams.
Understanding Ponzi Schemes
A Ponzi scheme is an investment scam where returns are paid to earlier investors using the capital from newer investors, rather than from legitimate profit earned. The scheme relies on a constant influx of new investments to continue paying the promised returns. Eventually, when the flow of new money slows down or stops, the scheme collapses, leaving the majority of investors with substantial financial losses.
Historical Context: Charles Ponzi and His Legacy
Charles Ponzi is the namesake of this deceptive practice. In the 1920s, Ponzi promised investors in Boston a 50% return within 45 days or 100% return in 90 days through arbitrage of international reply coupons. Initially, he paid returns as promised, not from profits, but from the investments of new participants. When his scheme unraveled, it resulted in losses exceeding $20 million (equivalent to about $270 million today).
Notable American Ponzi Schemes
1. Bernie Madoff: Perhaps the most notorious Ponzi scheme in recent history, Bernie Madoff’s fraud involved $65 billion. Madoff, a well-respected figure in the financial industry, promised steady, high returns through a secretive investment strategy. His scheme lasted for decades before collapsing in 2008, devastating thousands of investors, including individuals, charities, and institutional clients.
2. Allen Stanford: Through his company, Stanford Financial Group, Allen Stanford orchestrated a $7 billion Ponzi scheme, luring investors with fraudulent certificates of deposit issued by his offshore bank. Stanford promised high returns and lavish lifestyle benefits to his investors, which ultimately led to a 110-year prison sentence for the financier in 2012.
3. Tom Petters: In a scheme that lasted more than a decade, Tom Petters ran a $3.65 billion Ponzi scheme, using his company, Petters Group Worldwide. He claimed to buy and sell consumer electronics, but in reality, he used new investments to pay off old debts and fund his extravagant lifestyle. Petters was convicted in 2009 and sentenced to 50 years in prison.
4. Eric Dalius and Saivian: Eric Dalius, a prominent figure behind Saivian, a cashback program promising high returns, is under scrutiny for allegedly orchestrating a Ponzi scheme. Saivian enticed investors with promises of up to 20% cash back on everyday purchases. However, investigations suggest that the returns were paid using new investments rather than legitimate profits. The collapse of Saivian l
KYC Compliance: A Cornerstone of Global Crypto Regulatory FrameworksAny kyc Account
This presentation explores the pivotal role of KYC compliance in shaping and enforcing global regulations within the dynamic landscape of cryptocurrencies. Dive into the intricate connection between KYC practices and the evolving legal frameworks governing the crypto industry.
South Dakota State University degree offer diploma Transcriptynfqplhm
办理美国SDSU毕业证书制作南达科他州立大学假文凭定制Q微168899991做SDSU留信网教留服认证海牙认证改SDSU成绩单GPA做SDSU假学位证假文凭高仿毕业证GRE代考如何申请南达科他州立大学South Dakota State University degree offer diploma Transcript
Explore the world of investments with an in-depth comparison of the stock market and real estate. Understand their fundamentals, risks, returns, and diversification strategies to make informed financial decisions that align with your goals.
1. 7000 Cardinal Place
Dublin,OH 43017
www.cardinalhealth.com
FOR IMMEDIATE RELEASE
Contacts:
Media: Jim Mazzola Investors: Jason Strohm
(614) 757-3690 (614) 757-7542
jim.mazzola@cardinal.com jason.strohm@cardinal.com
CARDINAL HEALTH REPORTS SECOND-QUARTER RESULTS
• Revenue increases 13 percent to $21.8 billion
• EPS from continuing operations increases 17 percent to $0.77
• Non-GAAP diluted EPS from continuing operations up 20 percent to $0.83
• Company to broaden specialty pharmaceutical service offerings with
acquisition of SpecialtyScripts Pharmacy
DUBLIN, Ohio, Jan. 25, 2007 — Cardinal Health, the leading provider of products and services
supporting the health-care industry, today announced strong second-quarter results, highlighted by
double-digit revenue and earnings growth, solid contributions from all four continuing business
segments and a 17-percent increase in earnings per share.
For the second quarter ended Dec. 31, consolidated revenue increased 13 percent to $21.8 billion
and earnings from continuing operations rose 10 percent to $316 million, or $0.77 per share. On a
non-GAAP basis, earnings from continuing operations increased 15 percent to $341 million1, or 20
percent to $0.832 on a diluted per-share basis.
The company also announced an agreement to acquire SpecialtyScripts Pharmacy to broaden its
specialty pharmaceutical service offerings for pharmaceutical manufacturers. Terms were not
disclosed.
“We performed well during the quarter with solid, top-line growth in each business segment, while
maintaining the discipline in our operations to also deliver double-digit operating earnings growth in
all four segments,” said R. Kerry Clark, president and chief executive officer of Cardinal Health.
“We feel very good about the momentum we have established through the first half of the year.”
-more-
2. Cardinal Health Reports Second-Quarter Results
Page 2
Q2 FY07 Summary
Q2 FY07 Q2 FY06 Y/Y
Revenue $21.8 billion $19.3 billion 13%
Operating Earnings $512 million $457 million 12%
Non-GAAP Operating
Earnings3 $544 million $469 million 16%
Earnings from Continuing
Operations $316 million $286 million 10%
Non-GAAP Earnings from
Continuing Operations $341 million $297 million 15%
Diluted EPS from Continuing
Operations $0.77 $0.66 17%
Non-GAAP Diluted EPS from
Continuing Operations $0.83 $0.69 20%
Second quarter segment results:
(Segment results include equity compensation previously held at the corporate level. Due to
declining equity compensation levels, this had a favorable effect on segment earnings growth.
Results for the Pharmaceutical Technologies and Services segment are included in discontinued
operations for all periods presented).
• Revenue for the Healthcare Supply Chain Services-Pharmaceutical segment grew 13
percent to $19.2 billion, with direct-store-door (DSD) pharmaceutical sales growing 14 percent
to $10.2 billion and bulk customer sales growing 22 percent to $8.7 billion. Strong generic
sales combined with expense controls and synergies from the acquisition of the F. Dohmen
Company to drive a 19-percent increase in operating earnings to $328 million. This growth was
partially offset by lower pricing in the renewal of several large customer agreements.
• Revenue for the Healthcare Supply Chain Services-Medical segment increased 6
percent to nearly $1.9 billion and operating earnings grew 12 percent to $78 million. The
primary growth drivers for the segment included strong sales of laboratory and private
brand products, and continued momentum with surgery center customers and within the
segment’s Canadian operations. Selling, general and administrative (SG&A) expenses
declined as a percent of sales primarily due to disciplined expense control, reduced fuel
costs and productivity gains from facility and back-office consolidations.
• Revenue for the Clinical Technologies and Services segment increased 10 percent to
$662 million, with strong demand for both the Alaris and Pyxis product lines increasing
committed contracts above the first quarter. Operating earnings grew 16 percent from the
prior year to $92 million, while the segment continued to make investments in new products
and customer service initiatives. An upgrade to the flagship Pyxis MedStation was
released during the quarter. In addition, the company will demonstrate a fully integrated
bedside medication verification product in late February that integrates clinical data flow
across its Alaris, Pyxis and Care Fusion product lines and will enhance the company’s
medication management and patient safety offerings.
• Revenue for the Medical Products Manufacturing segment increased 15 percent to $455
million and operating earnings grew 21 percent to $51 million. Balanced results across the
segment contributed to the strong quarter, including revenue and earnings growth in
-more-
3. Cardinal Health Reports Second-Quarter Results
Page 3
infection prevention products, medical specialties and from Canadian operations. Ongoing
facility restructuring and operational excellence initiatives continued to deliver benefits
during the quarter through improved manufacturing efficiency.
Additional second-quarter and recent highlights include:
• Repurchase of $300 million of Cardinal Health shares during the quarter and more than
$900 million to date in the fiscal year.
• Announcement of plans to divest the Pharmaceutical Technologies and Services (PTS)
segment to focus resources on its four remaining segments serving health-care provider
customers, such as hospitals and pharmacies. (A $425-million tax asset associated with the
planned PTS divestiture has been recorded in discontinued operations and will be offset by
the related tax expense on any gain over net book value in the quarter that the transaction
closes.)
• Signing the agreement to acquire SpecialtyScripts Pharmacy. With this acquisition, Cardinal
Health intends to develop services for pharmaceutical manufacturers that complement and
leverage the company’s existing portfolio of nuclear pharmacies, third-party logistics offerings
and distribution services for blood and plasma products. The acquisition is expected to close in
the third quarter.
• Completing the first full quarter with integrated sales teams focused on hospital networks in the
U.S. and Canada, representing Cardinal Health’s entire portfolio of products, services and
integrated solutions.
Outlook
Cardinal Health reiterated its fiscal 2007 guidance range of $3.25 to $3.40 for non-GAAP diluted
EPS from continuing operations, which excludes the impact of proceeds from the planned sale of
its PTS business.
Conference Call
Cardinal Health will host a conference call and webcast at 11 a.m. Eastern Standard Time (EST)
to discuss the results. To access the call and corresponding slide presentation, go to the Investor
page at www.cardinalhealth.com. The conference call may also be accessed by calling 617-213-
8067, conference passcode 22400322. An audio replay will be available until 1 p.m. EST on
Feb. 1 at 617-801-6888, passcode 51497520. A transcript and audio replay will also be available
at www.cardinalhealth.com.
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $81 billion, global
company serving the health-care industry with a broad portfolio of products and services. Through
its diverse offerings, Cardinal Health delivers health-care solutions that help customers reduce
their costs, improve safety and productivity, and deliver better care to patients. The company
manufactures, packages and distributes pharmaceuticals and medical supplies, offers a range of
clinical services and develops automation products that improve the management and delivery of
supplies and medication for hospitals, physician offices and pharmacies. Ranked No. 19 on the
Fortune 500, Cardinal Health employs more than 55,000 people on six continents. More
information about the company may be found at www.cardinalhealth.com.
###
1
Non-GAAP earnings from continuing operations: Earnings from continuing operations excluding special
items and impairment charges and other, both net of tax.
-more-
4. Cardinal Health Reports Second-Quarter Results
Page 4
2
Non-GAAP diluted EPS from continuing operations: Non-GAAP earnings from continuing operations
divided by diluted weighted average shares outstanding.
3
Non-GAAP operating earnings: Operating earnings excluding special items and impairment charges and
other.
A reconciliation of the differences between these non-GAAP financial measures and their most directly
comparable GAAP financial measures is provided in the attached tables and at
http://www.cardinalhealth.com.
Except for historical information, all other information in this news release consists of forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These
forward-looking statements are subject to risks and uncertainties that could cause actual results to differ
materially from those projected, anticipated or implied. The most significant of these uncertainties are
described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to
those reports) and exhibits to those reports, and include (but are not limited to) the following: competitive
pressures in its various lines of business; the loss of one or more key customer or supplier relationships or
changes to the terms of those relationships; changes in the distribution patterns or reimbursement rates for
health-care products and/or services; the results, consequences, effects or timing of any inquiry or
investigation by or settlement discussions with any regulatory authority or any legal and administrative
proceedings, including shareholder litigation; uncertainties related to divesting the PTS segment, including
uncertainties as to the amount of proceeds and timing; the costs, difficulties and uncertainties related the
integration of acquired businesses; with respect to future share repurchases, the approval of the board of
directors, which is expected to consider Cardinal Health’s then-current stock price, earnings, cash flows,
financial condition and prospects as well as alternatives available to Cardinal Health at the time any such
action is considered; and general economic and market conditions. Except to the extent required by
applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.
-more-
5. CARDINAL HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)
Second Quarter
(in millions, except per Common Share amounts) 2007 2006 % Change
Revenue $ 21,784.6 $ 19,346.9 13 %
Cost of products sold 20,484.7 18,181.2 13 %
Gross margin 1,299.9 1,165.7 12 %
Selling, general and administrative expenses 755.6 696.9 8%
Impairment charges and other 12.6 (2.6) N.M.
Special items:
Restructuring charges 10.0 9.3 N.M.
Merger charges 9.1 5.9 N.M.
Other 0.5 (0.9) N.M.
Operating earnings 512.1 457.1 12 %
Interest expense and other 32.4 26.6 22 %
Earnings before income taxes and discontinued operations 479.7 430.5 11 %
Provision for income taxes 164.0 144.7 13 %
Earnings from continuing operations 315.7 285.8 10 %
Earnings from discontinued operations (net of tax benefit / (expense) of $416.1
and $(1.7) for the second quarter of fiscal 2007 and 2006, respectively) 423.6 18.2 N.M.
Net earnings $ 739.3 $ 304.0 143 %
Basic Earnings per Common Share:
Continuing operations $ 0.78 $ 0.67 16 %
Discontinued operations 1.06 0.04 N.M.
Net basic earnings per Common Share $ 1.84 $ 0.71 159 %
Diluted Earnings per Common Share:
Continuing operations $ 0.77 $ 0.66 17 %
Discontinued operations 1.03 0.04 N.M.
Net diluted earnings per Common Share $ 1.80 $ 0.70 157 %
Weighted Average Number of Shares Outstanding:
Basic 402.2 425.5
Diluted 410.6 431.9
- more -
6. CARDINAL HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)
Year-to-Date
(in millions, except per Common Share amounts) 2007 2006 % Change
Revenue $ 42,722.1 $ 38,199.3 12 %
Cost of products sold 40,221.7 35,932.0 12 %
Gross margin 2,500.4 2,267.3 10 %
Selling, general and administrative expenses 1,480.9 1,410.6 5%
Impairment charges and other 14.3 (0.6) N.M.
Special items:
Restructuring charges 21.8 16.8 N.M.
Merger charges 11.1 12.8 N.M.
Other 8.9 4.9 N.M.
Operating earnings 963.4 822.8 17 %
Interest expense and other 70.1 50.3 39 %
Earnings before income taxes and discontinued operations 893.3 772.5 16 %
Provision for income taxes 286.0 253.2 13 %
Earnings from continuing operations 607.3 519.3 17 %
Earnings from discontinued operations (net of tax benefit of $435.9 and $0.8
for fiscal 2007 and 2006 year-to-date, respectively) 402.7 13.0 N.M.
Net earnings $ 1,010.0 $ 532.3 90 %
Basic Earnings per Common Share:
Continuing operations $ 1.50 $ 1.22 23 %
Discontinued operations 1.00 0.03 N.M.
Net basic earnings per Common Share $ 2.50 $ 1.25 98 %
Diluted Earnings per Common Share:
Continuing operations $ 1.47 $ 1.20 23 %
Discontinued operations 0.98 0.03 N.M.
Net diluted earnings per Common Share $ 2.45 $ 1.23 99 %
Weighted Average Number of Shares Outstanding:
Basic 403.4 425.9
Diluted 412.0 431.7
- more -
7. CARDINAL HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (UNAUDITED)
December 31, June 30,
(in millions) 2006 2006
Assets
Cash and equivalents $ 1,003.3 $ 1,186.3
Short-term investments available for sale 467.1 498.4
Trade receivables, net 4,394.5 3,808.8
Current portion of net investment in sales-type leases 330.3 290.1
Inventories 7,309.2 7,493.0
Prepaid expenses and other 579.8 582.5
Assets held for sale and discontinued operations 3,093.9 2,743.2
Total current assets 17,178.1 16,602.3
Property and equipment, net 1,518.5 1,505.0
Net investment in sales-type leases, less current portion 758.9 754.7
Goodwill and other intangibles, net 4,391.3 4,283.4
Other assets 290.4 259.3
Total assets $ 24,137.2 $ 23,404.7
Liabilities and Shareholders' Equity
Current portion of long-term obligations and other short-term borrowings $ 48.9 $ 199.0
Accounts payable 8,984.7 8,907.8
Other accrued liabilities 2,139.6 1,948.8
Liabilities from businesses held for sale and discontinued operations 529.4 528.0
Total current liabilities 11,702.6 11,583.6
Long-term obligations, less current portion and other short-term borrowings 2,935.8 2,588.6
Deferred income taxes and other liabilities 591.0 741.8
Total shareholders' equity 8,907.8 8,490.7
Total liabilities and shareholders' equity $ 24,137.2 $ 23,404.7
- more -
8. CARDINAL HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Second Quarter Year-to-Date
(in millions) 2007 2006 2007 2006
Cash Flows From Operating Activities:
Net earnings $ 739.3 $ 304.0 $ 1,010.0 $ 532.3
Earnings from discontinued operations (423.6) (18.2) (402.7) (13.0)
Earnings from continuing operations 315.7 285.8 607.3 519.3
Adjustments to reconcile earnings from continuing operations
to net cash provided by operating activities:
Depreciation and amortization 77.0 69.9 155.4 145.6
Asset impairments 12.7 (4.1) 14.4 (2.9)
Equity compensation 34.1 46.7 71.5 120.7
Provision for bad debts 2.4 7.2 7.8 14.9
Change in operating assets and liabilities, net of
effects from acquisitions:
(Increase) / decrease in trade receivables (699.1) 101.4 (592.1) (160.1)
Decrease in inventories 64.4 65.7 184.1 88.9
Increase in net investment in sales-type leases (23.5) (23.1) (44.3) (61.9)
Increase in accounts payable 207.6 95.0 76.1 581.3
Other accrued liabilities and operating items, net (43.4) (60.5) 129.7 (4.3)
Net cash provided by / (used in) operating activities - continuing operations (52.1) 584.0 609.9 1,241.5
Net cash provided by operating activities - discontinued operations 5.7 74.1 29.5 151.2
Net cash provided by / (used in) operating activities (46.4) 658.1 639.4 1,392.7
Cash Flows From Investing Activities:
Acquisition of subsidiaries, net of divestitures and cash acquired (56.5) (75.8) (121.0) (72.5)
Proceeds from sale of property and equipment 9.7 3.2 13.3 3.5
Additions to property and equipment (85.4) (116.9) (154.0) (161.5)
Sale / (purchase) of investment securities available for sale, net (10.6) (219.1) 31.3 (319.2)
Net cash used in investing activities - continuing operations (142.8) (408.6) (230.4) (549.7)
Net cash used in investing activities - discontinued operations (11.5) (21.2) (7.9) (52.4)
Net cash used in investing activities (154.3) (429.8) (238.3) (602.1)
Cash Flows From Financing Activities:
Net change in commercial paper and short-term borrowings (101.8) 2.6 3.7 4.9
Reduction of long-term obligations (661.4) (90.6) (689.2) (92.8)
Proceeds from long-term obligations, net of issuance costs 850.0 500.4 851.7 500.3
Proceeds from issuance of Common Shares 18.0 33.7 75.3 68.5
Tax benefits from exercises of stock options 4.7 10.7 17.1 19.7
Dividends on Common Shares (36.5) (25.7) (73.4) (51.2)
Purchase of treasury shares (300.0) (412.9) (745.3) (412.9)
Net cash provided by / (used in) financing activities - continuing operations (227.0) 18.2 (560.1) 36.5
Net cash provided by / (used in) financing activities - discontinued operations (11.5) (2.3) (24.0) 3.3
Net cash provided by / (used in) financing activities (238.5) 15.9 (584.1) 39.8
Net increase / (decrease) in cash and equivalents (439.2) 244.2 (183.0) 830.4
Cash and equivalents at beginning of period 1,442.5 1,870.8 1,186.3 1,284.6
Cash and equivalents at end of period $ 1,003.3 $ 2,115.0 $ 1,003.3 $ 2,115.0
- more -
11. CARDINAL HEALTH, INC. AND SUBSIDIARIES
BUSINESS ANALYSIS
TOTAL COMPANY
Non-GAAP
Second Quarter Second Quarter
(in millions) 2007 2006 2007 2006
Revenue
Amount $21,785 $19,347
Growth Rate 13 % 8%
Operating Earnings
Amount $512 $457 $544 $469
Growth Rate 12 % 13 % 16 % 4%
Earnings from Continuing Operations
Amount $316 $286 $341 $297
Growth Rate 10 % 11 % 15 % 3%
Non-GAAP
Year-to-Date Year-to-Date
(in millions) 2007 2006 2007 2006
Revenue
Amount $42,722 $38,199
Growth Rate 12 % 8%
Operating Earnings
Amount $963 $823 $1,019 $857
Growth Rate 17 % 14 % 19 % 7%
Earnings from Continuing Operations
Amount $607 $519 $649 $544
Growth Rate 17 % 17 % 19 % 10 %
See the GAAP / Non-GAAP Reconciliation for definitions and calculations supporting the non-GAAP balances.
- more -
12. CARDINAL HEALTH, INC. AND SUBSIDIARIES
ASSET MANAGEMENT ANALYSIS
Second Quarter Year-to-Date
2007 2006 2007 2006
Receivable Days 19.2 14.4
Days Inventory on Hand 28 31
Debt to Total Capital 25 % 25 %
Net Debt to Capital 15 % 4%
Return on Equity1 34.1% 13.8% 23.5% 12.2%
Non-GAAP Return on Equity1 15.2% 14.6% 14.3% 12.9%
Return on Invested Capital1 13.85% 5.70% 9.51% 5.02%
Non-GAAP Return on Invested Capital1 6.53% 6.33% 6.22% 5.62%
Effective Tax Rate from Continuing Operations 34.2% 33.6% 32.0% 32.8%
Non-GAAP Effective Tax Rate from Continuing Operations 34.3% 32.9% 32.0% 32.5%
See the GAAP / Non-GAAP Reconciliation for definitions and calculations supporting the non-GAAP balances.
1
See definitions for explanation of changes in method of calculating these financial measures from prior quarters.
- more -
13. CARDINAL HEALTH, INC. AND SUBSIDIARIES
SCHEDULE OF NOTABLE ITEMS
Second Quarter Year-to-Date
(in millions, except per Common Share amounts) 2007 2006 2007 2006
Special Items
Restructuring charges $ (10.0) $ (9.3) $ (21.8) $ (16.8)
Merger charges (9.1) (5.9) (11.1) (12.8)
Other (0.5) 0.9 (8.9) (4.9)
Total special items (19.6) (14.3) (41.8) (34.5)
Tax benefit 7.1 1.6 13.1 9.0
Special items, net of tax $ (12.5) $ (12.7) $ (28.7) $ (25.5)
Decrease to diluted EPS from continuing operations $ (0.03) $ (0.03) $ (0.07) $ (0.06)
Impairment Charges and Other
Impairment charges and other $ (12.6) $ 2.6 $ (14.3) $ 0.6
Tax benefit / (expense) 0.1 (0.8) 0.6 (0.2)
Net impairment charges and other, net of tax $ (12.5) $ 1.8 $ (13.7) $ 0.4
Decrease to diluted EPS from continuing operations $ (0.03) $ - $ (0.03) $ -
Non-Recurring and Other Items
Total non-recurring $ - $ - $ - $ -
Vendor credit adjustment - 3.5 - (28.3)
Total non-recurring and other items - 3.5 - (28.3)
Tax benefit / (expense) - (1.1) - 9.2
Total non-recurring and other items, net of tax $ - $ 2.4 $ - $ (19.1)
Decrease to diluted EPS from continuing operations $ - $ 0.01 $ - $ (0.04)
Weighted Average Number of Diluted Shares Outstanding 410.6 431.9 412.0 431.7
- more -
14. CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
Second Quarter 2007 Year-to-Date 2007
Impairment Impairment
Special Charges and Special Charges and
(in millions, except per Common Share amounts) GAAP Items Other Non-GAAP GAAP Items Other Non-GAAP
Operating Earnings
Amount $512 $20 $13 $544 $963 $42 $14 $1,019
Growth Rate 12 % 16 % 17 % 19 %
Provision for Income Taxes $164 $7 - $171 $286 $13 $1 $300
Earnings from Continuing Operations
Amount $316 $13 $13 $341 $607 $29 $13 $649
Growth Rate 10 % 15 % 17 % 19 %
Diluted EPS from Continuing Operations
Amount $0.77 $0.03 $0.03 $0.83 $1.47 $0.07 $0.03 $1.57
Growth Rate 17 % 20% 23 % 25%
Second Quarter 2006 Year-to-Date 2006
Impairment Impairment
Special Charges and Special Charges and
GAAP Items Other Non-GAAP GAAP Items Other Non-GAAP
Operating Earnings
Amount $457 $14 ($3) $469 $823 $35 ($1) $857
Growth Rate 13 % 4% 14 % 7%
Provision for Income Taxes $145 $2 ($1) $146 $253 $9 - $262
Earnings from Continuing Operations
Amount $286 $12 ($2) $297 $519 $26 - $544
Growth Rate 11 % 4% 17 % 10 %
Diluted EPS from Continuing Operations
Amount $0.66 $0.03 - $0.69 $1.20 $0.06 - $1.26
The sum of the components may not equal the total due to rounding
- more -
15. CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
Second Quarter Year-to-Date
(in millions) 2007 2006 2007 2006
Return on Equity 1 34.1% 13.8% 23.5% 12.2%
Non-GAAP Return on Equity
Net earnings $ 739.3 $ 304.0 $ 1,010.0 $ 532.3
Special items, net of tax, in continuing operations 12.5 12.7 28.7 25.5
Special items, net of tax, in discontinued operations 1.7 4.3 3.1 6.0
Income tax benefit related to PTS discontinued operations (425.0) - (425.0) -
Adjusted net earnings $ 328.5 $ 321.0 $ 616.8 $ 563.8
Annualized 1,314.0 1,284.0 1,233.6 1,127.6
2
Divided by average shareholders' equity $ 8,664.5 $ 8,815.0 $ 8,606.5 $ 8,741.0
1
Non-GAAP return on equity 15.2% 14.6% 14.3% 12.9%
Second Quarter Year-to-Date
(in millions) 2007 2006 2007 2006
Return on Invested Capital1 13.85% 5.70% 9.51% 5.02%
Non-GAAP Return on Invested Capital
Net earnings $ 739.3 $ 304.0 $ 1,010.0 $ 532.3
Special items, net of tax, in continuing operations 12.5 12.7 28.7 25.5
Special items, net of tax, in discontinued operations 1.7 4.3 3.1 6.0
Interest expense and other, net of tax 20.2 16.7 43.8 31.4
Income tax benefit related to PTS discontinued operations (425.0) - (425.0) -
Adjusted net earnings $ 348.7 $ 337.7 $ 660.6 $ 595.2
Annualized $ 1,394.8 $ 1,350.8 $ 1,321.2 $ 1,190.4
3
Divided by average total invested capital $ 21,349.1 $ 21,324.7 $ 21,245.3 $ 21,190.2
1
Non-GAAP return on invested capital 6.53% 6.33% 6.22% 5.62%
1
See definitions for explanation of changes in method of calculating these financial measures from prior quarters.
2 The average shareholders' equity shown above is calculated using the average of the prior and current quarters except for year-to-
date which is calculated as the average of the prior years' fourth quarter plus each of the current year quarters.
3 The average total invested capital shown above is calculated using the average of the prior and current quarters except for year-to-
date which is calculated as the average of the prior year fourth quarter plus each of the current year quarters. Total invested capital
is calculated as the sum of the current portion of long-term obligations and other short-term borrowings, long-term obligations, current
portion of long-term obligations and other short-term borrowings in discontinued operations, long-term obligations in discontinued
operations, total shareholders' equity and unrecorded goodwill. Unrecorded goodwill is $9.7 billion for all periods presented. Current
portion of long-term obligations and other short-term borrowings in discontinued operations, and long-term obligations in discontinued
operations were $59.2 million, $46.6 million and $41.3 million at June 30, 2006, September 30, 2006 and December 31, 2006,
respectively, and $81.1 million, $84.7 million and $79.2 million at June 30, 2005, September 30, 2005 and December 31, 2005,
respectively.
- more -
16. CARDINAL HEALTH, INC. AND SUBSIDIARIES
GAAP / NON-GAAP RECONCILIATION
Second Quarter Year-to-Date
(in millions) 2007 2006 2007 2006
Effective Tax Rate from Continuing Operations 34.2% 33.6% 32.0% 32.8%
Non-GAAP Effective Tax Rate from Continuing Operations
Earnings before income taxes and discontinued operations $ 479.7 $ 430.5 $ 893.3 $ 772.5
Special items 19.6 14.3 41.8 34.5
Adjusted earnings before income taxes and discontinued operations $ 499.3 $ 444.8 $ 935.1 $ 807.0
Provision for income taxes $ 164.0 $ 144.7 $ 286.0 $ 253.2
Special items tax benefit 7.1 1.6 13.1 9.0
Adjusted provision for income taxes $ 171.1 $ 146.3 $ 299.1 $ 262.2
Non-GAAP effective tax rate from continuing operations 34.3% 32.9% 32.0% 32.5%
Second Quarter
2007 2006
Debt to Total Capital 25% 25%
Net Debt to Capital
Current portion of long-term obligations and other short-term borrowings $ 48.9 $ 374.9
Long-term obligations, less current portion and other short-term borrowings 2,935.8 2,555.5
Debt 2,984.7 2,930.4
Cash and equivalents (1,003.3) (2,115.0)
Short-term investments available for sale (467.1) (419.0)
Net debt $ 1,514.3 $ 396.4
Total shareholders' equity $ 8,907.8 $ 8,751.0
Capital $ 10,422.1 $ 9,147.4
Net debt to capital 15% 4%
Forward-Looking Non-GAAP Financial Measures
The Company presents non-GAAP diluted EPS from continuing operations and growth rate, non-GAAP return on equity, and non-GAAP effective tax
rate from continuing operations on a forward-looking basis. The Company is unable to provide a quantitative reconciliation of these forward-looking
non-GAAP measures to the most comparable forward-looking GAAP measures because the Company cannot reliably forecast special items and
impairment charges and other, which are difficult to predict and estimate and are primarily dependent on future events.
In addition, the Company's fiscal 2007 outlook and long-term growth rate goal for non-GAAP diluted EPS from continuing operations excludes the
impact of the proceeds from the planned PTS sale. As previously announced, the Company plans to use the net proceeds from the PTS sale to
repurchase shares, which is expected to add materially to fiscal 2008 earnings per share. The Company is unable to reliably forecast the impact of
the proceeds from the planned sale. Please note that the unavailable reconciling items could significantly impact the Company's future earnings.
- more -
17. CARDINAL HEALTH, INC. AND SUBSIDIARIES
DEFINITIONS
GAAP
Debt: long-term obligations plus short-term borrowings
Debt to Total Capital: debt divided by (debt plus total shareholders' equity)
Diluted EPS from Continuing Operations: earnings from continuing operations divided by diluted weighted
average shares outstanding
Effective Tax Rate from Continuing Operations: provision for income taxes divided by earnings before
income taxes and discontinued operations
Operating Cash Flow: net cash provided by / (used in) operating activities from continuing operations
Operating Earnings Mix: segment operating earnings divided by total operating earnings for all segments
1
Return on Equity: annualized net earnings divided by average shareholders' equity
Return on Invested Capital: annualized net earnings divided by (average total shareholders’ equity plus debt
2
plus unrecorded goodwill)
Revenue Mix: segment revenue divided by total revenue for all segments
NON-GAAP
Economic Profit: segment net operating earnings, after-tax minus (tangible capital multiplied by weighted
average cost of capital); tangible capital is the quarterly average calculated as total assets allocated to the
segment less (total liabilities allocated to the segment, goodwill and intangibles, cash and equivalents and short
term investments available for sale)
Economic Profit Margin: economic profit divided by revenue
Net Debt to Capital: net debt divided by (net debt plus total shareholders' equity)
Net Debt: debt minus (cash and equivalents and short-term investments available for sale)
Non-GAAP Diluted EPS from Continuing Operations: non-GAAP earnings from continuing operations divided
by diluted weighted average shares outstanding
Non-GAAP Earnings from Continuing Operations: earnings from continuing operations excluding special
items and impairment charges and other, both net of tax
Non-GAAP Earnings from Continuing Operations Growth Rate: (current period non-GAAP earnings from
continuing operations minus prior period non-GAAP earnings from continuing operations) divided by prior period
non-GAAP earnings from continuing operations
Non-GAAP Effective Tax Rate from Continuing Operations: (provision for income taxes adjusted for special
items) divided by (earnings before income taxes and discontinued operations adjusted for special items)
Non-GAAP Operating Earnings: operating earnings excluding special items and impairment charges and other
Non-GAAP Operating Earnings Growth Rate: (current period non-GAAP operating earnings minus prior
period non-GAAP operating earnings) divided by prior period non-GAAP operating earnings
Non-GAAP Operating Margin: non-GAAP operating earnings divided by revenue
Non-GAAP Return on Equity: (annualized current period net earnings plus special items minus special items
tax benefit plus $425.0 million income tax benefit related to PTS discontinued operations) divided by average
1
shareholders' equity
Non-GAAP Return on Invested Capital: (annualized net earnings plus special items minus special items tax
benefit plus interest expense and other plus $425.0 million income tax benefit related to PTS discontinued
2
operations) divided by (average total shareholders’ equity plus debt plus unrecorded goodwill)
1
Due to the classification of the Company's PTS segment as discontinued operations, beginning with the fiscal
2007 second quarter, the Company calculates return on equity on both a GAAP and non-GAAP basis with net
earnings in the numerator of the calculation instead of earnings from continuing operations as in prior quarters.
On a non-GAAP basis, the Company excludes the $425.0 million income tax benefit related to PTS discontinued
operations in addition to special items.
2
Due to the classification of the Company's PTS segment as discontinued operations, beginning with the fiscal
2007 second quarter, the Company calculates return on invested capital on both a GAAP and non-GAAP basis
with net earnings in the numerator of the calculation instead of operating earnings as in prior quarters. On a non-
GAAP basis, the Company excludes interest expense and other and the $425.0 million income tax benefit related
to PTS discontinued operations in addition to special items.
###